Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab on NSABP B-40. Homo sapiens

"Source of Patients Patients entered into this study were from the NSABP B-40 trial in which patients were randomized to one of three chemotherapy regimens with one-half of the patients also randomized to receive bevacizumab, based on reports of efficacy in the advanced disease setting. The three regimens were 1) four cycles of docetaxel followed by four cycles of doxorubicin plus cyclophosphamide, 2) same as regimen 1) except for the addition of capecitabine to docetaxel, 3) same as regimen 1) except for the addition of gemcitabine to docetaxel, Patients were stratified according to age at entry (less-than or equal to 49 or greater-than or equal to 50), clinical tumor size (2.0 to 4 cm or greater-than or equal to 4.1 cm), and hormone receptor status (estrogen receptor [ER] positive, progesterone receptor [PgR] positive, or both vs. ER and PgR negative). Eligibility criteria for NSABP B-40 included primary operable breast cancer diagnosed with a core needle biopsy with a palpable primary tumor at least 2.0 cm in diameter... (for more see dbGaP study page.)"